品牌:Quidel
貨號(hào):A310
品名:Polyclonal Antiserum to Human C9 Protein
規(guī)格:2.00 mL
商品詳情參考文獻(xiàn)相關(guān)資料
產(chǎn)品介紹
品名
Polyclonal Antiserum to Human C9 Protein
貨號(hào)
A310
規(guī)格
2.0 mL
標(biāo)本類型
Unformed stool
防腐劑
≤ 0.1% Sodium Azide
物種交叉反應(yīng)
Baboon, Horse, Rabbit, Hamster, Rhesus macaque
儲(chǔ)存
2°C to 8°C (≤ 30 days)
For long-term storage (> 30 days), aliquot and store at ≤ –20°C. Avoid repeated freeze-thaw.
使用說明
For Research Use Only. Not for use in diagnostic procedures
產(chǎn)品描述
Highly purified human C9 was isolated from normal serum and used to immunize goats. The anti-human C9 polyclonal antisera was tested against normal human plasma by double immunodiffusion, one-dimensional immunoelectrophoresis, quantitative radial immunodiffusion, and quantitative rocket immunoelectrophoresis. The antiserum was determined to be monospecific for C9 at varying concentrations
背景
C9 is a glycoprotein which is present in normal human serum/plasma at approximately 55 μg/mL. Primarily synthesized in the liver, C9 is a single-chain protein with a molecular weight of approximately 71 kD. This complement protein is amphiphilic in nature, and can be fragmented by human α-thrombin to produce C9a and C9b. The hydrophilic domain of the C9 complex becomes the C9a fragment and has an approximate molecular weight of 34 kD. The hydrophobic end becomes C9b fragment, which has an approximate molecular weight of 37 kD.
應(yīng)用
Applications of the C9 polyclonal antisera have been evaluated by various research facilities, and include Western Blot, 1 Immunodepletion, 2 Immunofluorescence, 3,4,5 IHC, 6,7 and ELISA. 8
參考文獻(xiàn)
Marks, R., Hindmarsh, E. Complement activation occurs on subendothelial extracelluslar matrix in vitro and is initiated by retraction or removal of overlying endothelial cells, J Immunol 160:6128-6136, 1998.
Barbashov, S., Wang C., Nicholson-Weller, A. Serum amyloid P component forms a stable complex with human C5b-6, J. Immunol. 158:3830-3835, 1997